Persistent postoperative opioid use after total hip or knee arthroplasty: A systematic review and meta-analysis

Hui Ping Tay, BPharm,* The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, Australia

Xinyi Wang, BPharm,* The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, Australia

Sujita W. Narayan, PhD, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, Australia

Jonathan Penm, PhD, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, and Department of Pharmacy, Prince of Wales Hospital, Randwick, New South Wales, Australia

Asad E. Patanwala, PharmD, MPH, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy, Sydney, New South Wales, and Department of Pharmacy, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

*Designated as co‒first authors.

Address correspondence to Dr. Patanwala (asad.patanwala@sydney.edu.au).

© American Society of Health‒System Pharmacists 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Purpose. To identify the proportion of patients with continued opioid use after total hip or knee arthroplasty.

Methods. This systematic review and meta-analysis searched Embase, MEDLINE, the Cochrane Central Register of Controlled Trials, and International Pharmaceutical Abstracts for articles published from January 1, 2009, to May 26, 2021. The search terms (opioid, postoperative, hospital discharge, total hip or knee arthroplasty, and treatment duration) were based on 5 key concepts. We included studies of adults who underwent total hip or knee arthroplasty, with at least 3 months postoperative follow-up.

Results. There were 30 studies included. Of these, 17 reported on outcomes of total hip arthroplasty and 19 reported on outcomes of total knee arthroplasty, with some reporting on outcomes of both procedures. In patients having total hip arthroplasty, rates of postoperative opioid use at various time points were as follows: at 3 months, 20% (95% CI, 13%-26%); at 6 months, 17% (95% CI, 12%-21%); at 9 months, 19% (95% CI, 13%-24%); and at 12 months, 16% (95% CI, 15%-16%). In patients who underwent total knee arthroplasty, rates of postoperative opioid use were as follows: at 3 months, 26% (95% CI, 19%-33%); at 6 months, 20% (95% CI, 17%-24%); at 9 months, 23% (95% CI, 17%-28%); and at 12 months, 21% (95% CI, 12%-29%). Opioid naïve patients were less likely to have continued postoperative opioid use than those who were opioid tolerant preoperatively.

Conclusion. Over 1 in 5 patients continued opioid use for longer than 3 months after total hip or knee arthroplasty. Clinicians should be aware of this trajectory of opioid consumption after surgery.

Keywords: hip replacement arthroplasty, knee replacement arthroplasty, opioid analgesics, postoperative pain, pain management
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are among the most common elective procedures.\textsuperscript{1-3} The demand for these surgeries is projected to increase substantially in the next decade.\textsuperscript{4} Postoperative pain after these surgeries is often severe, and opioid use in the immediate postoperative period is indicated.\textsuperscript{5-7} However, there is lack of information regarding how long patients continue to require opioids after hospitalization. Increasing duration of opioid use after surgery has been associated with opioid dependence, abuse, and overdose.\textsuperscript{8} Thus, international guidelines for acute postoperative pain recommend that opioids should be used only when necessary, at the lowest effective dose, and for the shortest duration.\textsuperscript{9,10}

A better understanding of the trajectory of opioid use following THA or TKA is needed to help guide clinicians and patients for care planning and harm prevention. Identifying patients who are susceptible to prolonged opioid use allows processes to be implemented to mitigate this risk. In patients undergoing THA or TKA, the surgery itself is meant to alleviate pain by correcting the underlying cause. Thus, prolonged use of opioids postoperatively is not routinely expected.\textsuperscript{11} Guidance endorsed by the US Centers for Disease Control and Prevention suggest opioid prescribing for less than 14 days for severe pain after THA or TKA.\textsuperscript{11} Also, chronic severe postsurgical pain has been shown to occur in 6\% to 15\% of patients after THA or TKA.\textsuperscript{12} Previous reviews have assessed the prevalence of postoperative opioid use after general surgery and trauma.\textsuperscript{13-15} However, there are no systematic reviews or meta-analyses regarding this topic in patients undergoing THA or TKA. Therefore, the primary aim of this systematic review and meta-analysis was to identify the proportion of adult patients taking opioids at 3 to 12 months after THA or TKA. Our secondary objective was to compare duration of postoperative opioid use between patients who were opioid naïve and those who were opioid tolerant preoperatively.
Methods

Protocol and registration. The review was developed and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. The review protocol was registered in the PROSPERO international prospective register of systematic reviews (registration number CRD42020145241). There was no funding source for this systematic review and meta-analysis.

Information source and search strategy. Database searches were conducted in Embase, MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), and International Pharmaceutical Abstracts. The search terms (opioid, postoperative, hospital discharge, total hip or knee arthroplasty, and treatment duration) were based on 5 key concepts and adapted for each database search. The full electronic search strategy for Embase is provided in the supplementary appendix. The search was limited to articles on research in humans, published in the English language, and with a publication year from 2009 to the present; the latest search was conducted on May 26, 2021. Any studies published prior to this timeframe were not considered to be reflective of contemporary practice. The bibliographies of included studies were screened to identify any additional literature that met our eligibility criteria.

Eligibility criteria. The following question was used to identify relevant articles: In adult patients having THA or TKA, what is the duration of postoperative opioid use in randomized controlled trials and observational studies? Studies were included if the proportion of patients taking an opioid at a postoperative time point (3-12 months) were reported or could be calculated based on the data presented. Studies were excluded if the
postoperative follow-up period was less than 3 months or involved cancer or palliative care or if the data for THA or TKA could not be extracted separately.

**Study selection.** After removal of duplicate publications, titles and abstracts were screened for potentially relevant studies. Full-text articles were retrieved and reviewed to identify studies that met the eligibility criteria. Two reviewers independently performed database searches and assessed the eligibility of studies. Any inconsistencies were resolved through discussion with a third reviewer.

**Data extraction.** Data extracted included author, year of publication, country of origin, study design, data source, sample size, patient age, surgical procedures, duration of follow-up, definition of opioid use, and the proportion of patients taking an opioid at postoperative time points defined for each study. The opioid data was collected for the total sample and also for predefined subgroups. The subgroups of interest were those who had preoperative opioid consumption (ie, opioid-tolerant patients) and those who did not have preoperative opioid consumption (ie, opioid-naïve patients). One reviewer extracted the data, which was verified by a second reviewer. Inconsistencies between reviewers were resolved through discussion with a third reviewer.

**Risk of bias assessment.** The quality of included studies was assessed independently by 2 reviewers (H.P.T. and X.W.) using the Newcastle-Ottawa Quality Assessment Scale for cohort studies, with a maximum score of 9 stars. The scale has 3 domains: (1) selection of the study groups, (2) comparability of the groups, and (3) ascertainment of outcome. A maximum of 9 stars can be awarded to studies of the highest quality. Discrepancies regarding quality assessment were resolved through discussion or in consultation with a third reviewer.
Outcomes

The primary outcome measure was the duration of postoperative opioid use, reported here as the proportion of patients taking opioids at 3 months, 6 months, 9 months, or 12 months following THA or TKA. The secondary outcome was the proportion of patients with prolonged postoperative opioid use among opioid-naïve and opioid-tolerant patients. The definition of prolonged or persistent opioid use has not been established and varies substantially between studies. Based on the definition of chronic postsurgical pain, we used a time period cutoff of 3 months. However, we acknowledge that shorter periods may be more desirable for assessing what is considered optimal use.

Quantitative analysis and meta-analysis. All studies that satisfied our selection criteria and research question were included in the systematic review. The results were first categorized by type of surgery (THA or TKA). The overall proportion of patients with opioid use was reported for each time period within these strata. For each type of surgery, the groups were stratified by preoperative opioid use status (opioid naïve or tolerant). The Metaprop package in STATA, version 16.0 (StataCorp LLC, College Station, TX) was used for the meta-analysis. The results were reported as proportions with 95% confidence intervals (CIs). A random effects model with inverse variance was used. Heterogeneity was determined according to definitions in the Cochrane handbook, with an $I^2$ value of <40% indicating “might not be important heterogeneity”; a value of 30% to 60%, “may represent moderate heterogeneity”; a value of 50% to 90%, “may represent substantial heterogeneity”; and a value of >75%, “considerable heterogeneity.”

Sensitivity analysis. There was considerable heterogeneity present, and we considered that this could be because of the difference between opioid-naïve and opioid-tolerant patients. Thus, the results were stratified by preoperative opioid consumption to
address this possibility. Furthermore, some studies were conducted in military personnel; as this population could be different with regard to postoperative opioid use, the analysis was repeated using only studies involving civilian populations.

**Definitions of pre- and postoperative opioid use.** The definitions of preoperative and postoperative opioid users for each study are provided in Table 1. Most studies reported opioid use based on opioid prescriptions filled at a certain time (eg, 3 months postoperatively) or within a timeframe (eg, 3-9 months postoperatively). Studies that reported opioid use within a timeframe were categorized according to the starting point of the timeframe. For example, patients who had documented opioid use between 3 and 6 months after surgery were considered as taking opioids for at least 3 months postoperatively.

Some studies specified a minimum threshold of opioid consumption based on dose and duration (eg, a minimum of 20 mg per day of morphine equivalents for 30 continuous days within 6 months after surgery) for a patient to be considered a postoperative opioid user. Participants who did not reach this threshold were considered to be nonusers or a separate group; however, the duration of postoperative opioid use could not be ascertained separately for the latter group. We defined postoperative opioid users as patients who met the specific criteria used in the respective studies and considered the remaining patients as non-opioid users. The same applied to the definitions of preoperative opioid use.

**Results**

**Study selection.** The initial search yielded 1,363 articles. After removal of duplicates and screening of titles and abstracts, 82 articles were retrieved for full-text review. Thirty
articles\textsuperscript{22-51} met the eligibility criteria and were included. Figure 1 shows a PRISMA flow diagram that summarizes the selection process.

**Study characteristics.** Table 1 summarizes the characteristics of the 30 studies (total \( n = 1,148,318 \)) included in this review. Twenty-six studies\textsuperscript{22-25,27-33,37-51} were conducted in the United States, 2 studies in Australia,\textsuperscript{34,35} 1 study in Denmark,\textsuperscript{36} and 1 study\textsuperscript{26} included participants from both the United States and United Kingdom.\textsuperscript{26} Most (\( n = 29 \)) were observational retrospective studies,\textsuperscript{22,31,33-51} and 1 was a secondary analysis of a prospective study.\textsuperscript{32} Data on opioid use were sourced from administrative claims databases (\( n = 15 \)),\textsuperscript{22,27,29,31,33-35,41,45,47,50} a nationwide reimbursed prescription database (\( n = 1 \)),\textsuperscript{36} a state-controlled substance prescription monitoring registry (\( n = 7 \)),\textsuperscript{30,37,39,40,48,49,51} electronic medical records (\( n = 7 \)),\textsuperscript{26,30,38,42-44,46} surgeon surveys (\( n = 1 \)),\textsuperscript{31} or patient surveys (\( n = 1 \)).\textsuperscript{32} Four studies were conducted in veterans or military settings.\textsuperscript{33-35,41} Patient sex was reported in 23 studies.\textsuperscript{22-28,30,31,33-39,41-47,49-51} The proportion of females in these studies ranged from 6.5\% to 67\%.

**Risk of bias assessment.** Supplementary Table 1 presents the results from the risk of bias assessment based on the Newcastle-Ottawa scale. One study was assigned 5 stars,\textsuperscript{41} and the remainder were assigned 7 to 9 stars. Fourteen studies were deemed to involve risk of bias in the selection of study groups.\textsuperscript{30-32,34-36,38-42,49-51}

**Postoperative opioid use duration.** In total, 19 studies\textsuperscript{22-27,29,30,32-35,38,42-44,46,49,50} reported postoperative opioid use at 3 months, 16 studies\textsuperscript{22,23,29,32,33,37,39,40,42-48,51} at 6 months, 8 studies\textsuperscript{22,23,29,36,42-44,46} at 9 months, and 6 studies\textsuperscript{22,23,28,29,31,41} at 12 months (Table 2).

**Total hip arthroplasty.** Seventeen studies reported opioid use after THA.\textsuperscript{22,24,25,28,30,32,35,36,38,39,42,46-51} The proportion of patients taking prescription opioids after
THA were as follows (Figure 2): at 3 months, 20% (95% CI, 13%-26%); at 6 months, 17% (95% CI, 12%-21%); at 9 months, 19% (95% CI, 13%-24%); and at 12 months, 16% (95% CI, 15%-16%). There was considerable heterogeneity at each time point ($I^2$ values of 99%-100%). The proportions of patients in the opioid-naïve and opioid-tolerant subsets are reported in Table 3 and also depicted in the forest plots in the supplementary material. We also conducted a sensitivity analysis by excluding studies involving military or veteran populations; the results were similar (Table 3).

**Total knee arthroplasty.** Nineteen studies reported opioid use after TKA. The proportions of patients taking prescription opioids after TKA were as follows (Figure 3): at 3 months, 26% (95% CI, 19%-33%); at 6 months, 20% (95% CI, 17%-24%); at 9 months, 23% (95% CI, 17%-28%); and at 12 months, 21% (95% CI, 12%-29%). There was considerable heterogeneity at each time point ($I^2$ values of 99%-100%). The proportions of patients in the opioid-naïve and opioid-tolerant subsets are shown in Table 4 and also depicted in the forest plots in the supplementary material. In the sensitivity analysis that excluded studies involving military or veteran populations, the opioid consumption appeared to be lower at 12 months (Table 4), suggesting greater chronic opioid use in military versus civilian populations.

**Trend of postoperative opioid use across time points.** Ten studies reported outcomes at multiple time points. All studies showed a trend of decreasing opioid use as postoperative duration increased. The decline in the proportion of individuals using opioids between 3 and 6 months postoperatively was larger than the decline among those using opioids between 6 and 9 months or between 9 and 12 months postoperatively. For example, in the study by Namba et al., the proportion of opioid users dropped sharply from
42.1% to 32.2% between 3 months and 6 months and then decreased slightly to 29.6% at 9 months after surgery. Data from all 10 studies are reported in Table 2.

**Preoperative opioid use status.** A total of 17 studies\textsuperscript{22-24,28-36,39,40,45,48,51} stratified the reporting of postoperative opioid use based on whether or not patients had preoperative opioid consumption. Preoperative opioid users showed a higher risk of continuing postoperative opioid than nonusers at all evaluated time points. For instance, at 3 months after THA, the proportion with continued opioid use was 10% (95% CI, 6%-15%) for opioid-naïve patients and 47% (95% CI, 34%-60%) for opioid-tolerant patients. Similarly, 3 months after TKA, the proportions with continued opioid use were 11% (95% CI, 5%-18%) and 60% (95% CI, 53%-68%) for opioid-naïve and opioid-tolerant patients, respectively. These data are reported for each time point for both THA and TKA in Table 3 and Table 4, respectively. In the subgroup of preoperative opioid users, studies that were conducted in veterans or in military settings\textsuperscript{33-35} reported higher proportions of postoperative opioid users than studies that were conducted in the general population (Table 2).

**Discussion**

To our knowledge, this is the first systematic review to focus on the duration of opioid use after THA or TKA. Overall, more than 1 in 5 patients had continued opioid use that was sustained for 12 months postoperatively. However, there were substantial differences between those who were opioid naïve versus opioid tolerant preoperatively. For example, while about 10% of patients in the opioid-naïve group continued opioid use postoperatively, up to half of the patients who were opioid tolerant had continued use. Thus, this is an important factor that should be considered when determining risk of prolonged postoperative opioid consumption. Existing guidelines generally recommend
opioid prescriptions of no more than 3 to 7 days for the treatment of acute pain.\textsuperscript{10,52,53} Although recovery after TKA or THA may take longer, opioids should not be prescribed for longer than 14 days for most patients.\textsuperscript{11} Given the high volumes of THA and TKA procedures, the findings showed that a large proportion of patients might be taking opioids for longer than the recommended duration, which has the potential for harm.

Regarding trends of opioid use across the various study periods, it was expected that the proportion of patients taking opioids would decrease with time. However, the decline appeared to be greater in the early postoperative period (from 3 to 6 months after surgery). This suggests that the likelihood of opioid cessation decreases with the duration of postoperative opioid exposure. A possible explanation for the observed slower decline in the rate of opioid use in the late postoperative period is the increased risk of developing opioid dependence and addiction over time.\textsuperscript{54} Also, the longer patients continue to take opioids, the more difficult it may be to achieve cessation of therapy. Clinicians may be less likely to successfully cease therapy in these circumstances. Although approximately half of patients with preexisting opioid use had persistent use of opioids post surgery, we would expect this proportion to be lower because chronic severe postsurgical pain has been shown to occur in 6\% to 15\% of patients after THA or TKA.\textsuperscript{12}

There was considerable heterogeneity in duration of opioid use between studies. This could be attributed to a lack of consistency in the definitions of postoperative opioid use. A recent study by Jivraj et al\textsuperscript{19} reported a more than 100-fold difference in the rates of persistent opioid use when different definitions were applied to the same patient cohort. The influence of opioid use definitions on the reported incidence of opioid use could have masked the effect of other factors such as patient characteristics and prescribing pattern. This makes it difficult to compare results across studies. The issue of inconsistency in
definitions has also been discussed by authors of previous studies.\textsuperscript{13,14} In relation to this issue, an expert consensus statement\textsuperscript{55} has recommended standard definitions of persistent postoperative opioid use based on preoperative opioid use status. For opioid-naïve patients (ie, those with no history of opioid use in the 90 days before surgery), persistent postoperative opioid use was defined as filling a prescription for at least a 60 days’ supply of opioids during days 90 to 365 after surgery. For preoperative opioid users, persistent use was defined as any increase in opioid use relative to baseline during days 90 to 365 after surgery.\textsuperscript{55} These definitions could be a good starting point to improve the comparability of future studies. We were unable to apply this definition to the reviewed studies because it was not possible to identify patients fulfilling these criteria due to variable study reporting. Nonetheless, we found great differences in outcomes between opioid-naïve and opioid-tolerant patients, which suggests that the definitions used were able to discriminate between patients adequately.

The higher proportion of persistent postoperative opioid use in the subgroup of preoperative opioid users further supports the findings from previous studies that the history of opioid use before surgery is a major risk factor for long-term or chronic postoperative opioid use.\textsuperscript{56,57} Preoperative opioid use appeared to have a different magnitude of effect across studies. This finding could be explained in part by the inconsistency in definitions of preoperative opioid users specified in each study. History of opioid use is a well-established risk factor for postoperative prolonged and chronic opioid use. Preoperative opioid prescribing may be modified to reduce the risk of prolonged postoperative opioid use.\textsuperscript{58}

Codeine and tramadol were not considered as opioids in some studies included in our review.\textsuperscript{22,23,27,38} They are 2 very commonly used opioid analgesics. The exclusion of these
2 opioids probably led to the underestimation of opioid use in those studies. Codeine can be used for the treatment of indications other than pain, such as for its antitussive properties. Thus, it would be hard to differentiate between indications for this opioid. In addition, codeine and tramadol are frequently not included in studies because they are less potent than other opioids such as oxycodone and are thought to pose a lower risk of abuse or addiction.\textsuperscript{59} However, studies on the safety of tramadol versus other opioids have reported contradictory findings.\textsuperscript{60-62} For example, a recent study found that tramadol posed a similar or somewhat higher risk of prolonged use after surgery relative to other short-acting opioids.\textsuperscript{61} The abuse and misuse potential of codeine and tramadol and their contribution to the opioid epidemic should not be overlooked. Future research should include codeine and tramadol as opioids or analyze their use in subgroup analyses.

One of the strengths of this review is that the included studies reflect contemporary practice, because the search was limited to the past 12 years and most of the included studies were published within the past 2 years. The outcomes were presented at several time points, allowing us to observe trends of opioid use in the postoperative period. This review should be considered in the light of some limitations. First, the majority of the studies measured opioid use status based solely on prescriptions filled. This may not have reflected the actual opioid consumption by the patients, because some filled prescriptions may have gone unused.\textsuperscript{63} Data on the dose or the number of tablets prescribed were also unavailable. Second, there was substantial variability between studies in term of population baseline characteristics, data source and collection, definitions of opioid use status, and reporting of results. This contributed to variability between studies. Thirdly, studies did not report whether persistent opioid use was for indications or comorbidities other than postoperative pain. It is possible that some patients were taking opioids for other pain
conditions. Finally, studies did not stratify the results by other factors that could influence persistent opioid use, such as history of substance abuse or mental health.

Future research should consider using prospective study designs to measure patient-reported postoperative opioid consumption. The reporting of other data, such as pain assessments and patients’ perceptions and experiences of pain and opioid analgesics, could be helpful to give an overall picture of how patient factors affect postoperative opioid use. More research is needed to investigate non–patient-related risk factors, such as prescribing and dispensing habits, healthcare system characteristics, and types of opioid medications, that may be associated with persistent postoperative opioid use. Identification of contributing factors will facilitate the development of possible interventions. This review highlights and quantifies the problem of prolonged opioid use after THA or TKA. Patients with persistent opioid use should be evaluated for opioid deprescribing. There is an important role for opioid stewardship and, potentially, for pharmacists to address this issue. The reason for continued opioid use needs to be elucidated. For example, THA and TKA are meant to alleviate joint pain. If surgery is successful, it is anticipated that chronic opioid use would not be indicated.

Conclusion

Among patients who have THA or TKA, over 20% have persistent opioid use for longer than 3 months postoperatively, and this use may be sustained for over 12 months. Opioid-naïve patients are less likely to have continued postoperative opioid use than those who are opioid tolerant preoperatively. Clinicians involved in the care of these patients should be aware of this trajectory of opioid consumption after surgery.
Disclosures

The authors have declared no potential conflicts of interest.
References

1. Canadian Institute for Health Information. Inpatient hospitalization, surgery, newborn, alternate level of care and childbirth statistics, 2017-2018. In: Canadian Institute for Health Information; 2019.

2. Australian Institute of Health and Welfare. Australian hospital statistics 2012–13. In: Australian Institute of Health and Welfare; 2014.

3. Fingar KR, Stocks C, Weiss AJ, Steiner CA. Most frequent operating room procedures performed in US hospitals, 2003–2012. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Agency for Health Care Policy and Research; 2014. Accessed July 16, 2021. https://www.ncbi.nlm.nih.gov/books/NBK274246/

4. Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the US, 2014 to 2030. J Bone Joint Surg Am. 2018;100:1455-1460.

5. Lespasio MJ, Guarino AJ, Sodhi N, Mont MA. Pain management associated with total joint arthroplasty: a primer. Perm J. 2019;23:18-169.

6. Sommer M, de Rijke JM, van Kleef M, et al. The prevalence of postoperative pain in a sample of 1490 surgical inpatients. Eur J Anaesth. 2008;25:267-274.

7. Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain. 2011;152:566-572.

8. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ Open. 2018;360:j5790.

9. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. JAMA. 2016;315:1624-1645.
10. Royal Australian College of General Practitioners. *Prescribing Drugs of Dependence in General Practice, Part C2: The Role of Opioids in Pain Management*. Royal Australian College of General Practitioners; 2017.

11. US Centers for Disease Control and Prevention. Postsurgical pain. Accessed July 5, 2021. https://www.cdc.gov/acute-pain/postsurgical-pain/index.html

12. Schug SA, Bruce J. Risk stratification for the development of chronic postsurgical pain. *Pain Rep.* 2017;2:e627.

13. Hinther A, Abdel-Rahman O, Cheung WY, et al. Chronic postoperative opioid use: a systematic review. *World J Surg.* 2019;43:2164-2174.

14. Page MG, Kudrina I, Zomahoun HTV, et al. A systematic review of the relative frequency and risk factors for prolonged opioid prescription following surgery and trauma among adults. *Ann Surg.* 2020;271(5):845-854.

15. Mohamadi A, Chan JJ, Lian J, et al. Risk factors and pooled rate of prolonged opioid use following trauma or surgery: a systematic review and meta-(regression) analysis. *J Bone Joint Surg Am.* 2018;100:1332-1340.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;339:b2535.

17. Duration of postoperative opioid use in adults after hip or knee surgery: a systematic review. PROSPERO, 2020. Accessed July 16, 2020. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=145241.

18. Wells GA, Shea B, O'Connell B, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. Published 2014. Accessed August 31, 2019. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
19. Jivraj NK, Raghavji F, Bethell J, et al. Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study. *Anesthesiology.* 2020;132(6):1528-1539.

20. *Stata Statistical Software: Release 16.* StataCorp LLC; 2019.

21. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev.* 2019;10:ED000142.

22. Bedard NA, Pugely AJ, Dowdle SB, et al. Opioid use following total hip arthroplasty: trends and risk factors for prolonged use. *J Arthroplasty.* 2017;32:3675-3679.

23. Bedard NA, Pugely AJ, Westermann RW, et al. Opioid use after total knee arthroplasty: trends and risk factors for prolonged use. *J Arthroplasty.* 2017;32:2390-2394.

24. Bell JE, Sequeira SB, Chen DQ, et al. Preoperative pain management: is tramadol a safe alternative to traditional opioids before total hip arthroplasty? *J Arthroplasty.* 2020;35(10):2886-2891.e1.

25. Bolarinwa SA, Casp AA, Cancienne JM, et al. Narcotic use and total hip arthroplasty. *Hip Int.* 2019;29:379-384.

26. Burn E, Weaver J, Morales D, et al. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study. *Lancet Rheumatol.* 2019;1:e229-e36.

27. Cancienne JM, Patel KJ, Browne JA, Werner BC. Narcotic use and total knee arthroplasty. *J Arthroplasty.* 2018;33:113-118.
28. Cook DJ, Kaskovich SW, Pirkle SC, et al. Benchmarks of duration and magnitude of opioid consumption after total hip and knee arthroplasty: a database analysis of 69,368 patients. *J Arthroplasty*. 2019;34:638-644.e1.

29. DeMik DE, Carender CN, Shamrock AG, et al. Opioid use after total knee arthroplasty: does tramadol have lower risk than traditional opioids? *J Arthroplasty*. 2020;35:1558-1562.

30. Dwyer MK, Tumpowsky CM, Hiltz NL, et al. Characterization of post-operative opioid use following total joint arthroplasty. *J Arthroplasty*. 2018;33:668-672.

31. Franklin PD, Karbassi JA, Li W, et al. Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction. *J Arthroplasty*. 2010;25:12-16.

32. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. *Pain*. 2016;157:1259-1265.

33. Hadlandsmyth K, Vander Weg MW, McCoy KD, et al. Risk for prolonged opioid use following total knee arthroplasty in veterans. *J Arthroplasty*. 2018;33:119-123.

34. Hansen CA, Inacio MCS, Pratt NL, et al. Chronic use of opioids before and after total knee arthroplasty: a retrospective cohort study. *J Arthroplasty*. 2017;32:811-817.e1.

35. Inacio MC, Hansen C, Pratt NL, et al. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. *BMJ Open*. 2016;6:e010664.

36. Jorgensen CC, Petersen M, Kehlet H, Aavang EK. Analgesic consumption trajectories in 8975 patients 1 year after fast-track total hip or knee arthroplasty. *Eur J Pain (London, England)*. 2018;22:1428-1438.
37. Kalbian IL, Bonaddio VA, Tan TL, et al. Reduced opioid requirements following unicompartmental knee arthroplasty compared with total knee arthroplasty. *Bone Joint J.* 2019;101-B(7)(suppl C):22-27.

38. Karhade AV, Schwab JH, Bedair HS. Development of machine learning algorithms for prediction of sustained postoperative opioid prescriptions after total hip arthroplasty. *J Arthroplasty.* 2019;34:2272-2277.e1.

39. Kim K, Chen KK, Roof M, et al. The effects of preoperative chronic opioid use in total hip arthroplasty. *J Clin Orthop Trauma.* 2020;11:73-78.

40. Kim KY, Anoushiravani AA, Chen KK, et al. Preoperative chronic opioid users in total knee arthroplasty—which patients persistently abuse opiates following surgery? *J Arthroplasty.* 2018;33:107-112.

41. Kuo AC, Raghunathan K, Lartigue AM, et al. Freedom from opioids after total knee arthroplasty. *J Arthroplasty.* 2019;34:893-897.

42. Namba RS, Inacio MCS, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. *Acta Orthop.* 2016;87:37-43.

43. Namba RS, Inacio MCS, Pratt NL, et al. Persistent opioid use following total knee arthroplasty: a signal for close surveillance. *J Arthroplasty.* 2018;33:331-336.

44. Namba RS, Singh A, Paxton EW, Inacio MCS. Patient factors associated with prolonged postoperative opioid use after total knee arthroplasty. *J Arthroplasty.* 2018;33:2449-2454.

45. Politzer CS, Kildow BJ, Goltz DE, et al. Trends in opioid utilization before and after total knee arthroplasty. *J Arthroplasty.* 2018;33:S147-S153.e1.

46. Prentice HA, Inacio MCS, Singh A, et al. Preoperative risk factors for opioid utilization after total hip arthroplasty. *J Bone Joint Surg Am.* 2019;101:1670-1678.
47. Schwartz AM, Wilson JM, Farley KX, et al. Modifiability of depression’s impact on early revision, narcotic usage, and outcomes after total hip arthroplasty: The impact of psychotherapy. *J Arthroplasty*. 2020;35(10):2904-2910.

48. Tan TL, Rondon AJ, Wilt Z, et al. Understanding opioid use after total hip arthroplasty: a comprehensive analysis of a mandatory prescription drug monitoring program. *J Am Acad Orthop Surg*. 2020;28(20):e917-e922.

49. Ruddell JH, Reid DBC, Shah KN, et al. Larger initial opioid prescriptions following total joint arthroplasty are associated with greater risk of prolonged use. *J Bone Joint Surg Am*. 2021;103:106-114.

50. Soffin EM, Wilson LA, Liu J, et al. Association between sex and perioperative opioid prescribing for total joint arthroplasty: a retrospective population-based study. *Br J Anaesth*. 2021;126(6):1217-1225.

51. Wilt ZT, Tan TL, Rondon AJ, et al. Preoperative sedative use and other risk factors for continued narcotic use after total knee arthroplasty: a comprehensive analysis of a mandatory database. *Orthopedics*. 2020;44:E50-E54.

52. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain*. 2016;17:131-157.

53. Macintyre PE, Schug SA. *Acute Pain Management: A Practical Guide*. 4th ed. CRC Press; 2015.
54. Edlund MJ, Martin BC, Russo JE, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. *Clin J Pain.* 2014;30:557-564.

55. Kent ML, Hurley RW, Oderda GM, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative-4 joint consensus statement on persistent postoperative opioid use: definition, incidence, risk factors, and health care system initiatives. *Anesth Analg.* 2019;129:543-552.

56. Williams BT, Redlich NJ, Mickschl DJ, Grindel SI. Influence of preoperative opioid use on postoperative outcomes and opioid use after arthroscopic rotator cuff repair. *J Shoulder Elbow Surg.* 2019;28:453-460.

57. Goplen CM, Verbeek W, Kang SH, et al. Preoperative opioid use is associated with worse patient outcomes after total joint arthroplasty: a systematic review and meta-analysis. *BMC Musculoskelet Disord.* 2019;20:234.

58. Nguyen L-CL, Sing DC, Bozic KJ. Preoperative reduction of opioid use before total joint arthroplasty. *J Arthroplasty.* 2016;31:282-287.

59. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. *Drug Saf.* 1996;15:8-29.

60. O’Malley PA. Think tramadol is a safer option? Think again!: prescribing considerations for the clinical nurse specialist. *Clin Nurse Spec.* 2019;33:209-211.

61. Thiels CA, Habermann EB, Hooten WM, Jeffery MM. Chronic use of tramadol after acute pain episode: cohort study. *BMJ Open.* 2019;365:1849.

62. Zhang H, Liu Z. The investigation of tramadol dependence with no history of substance abuse: a cross-sectional survey of spontaneously reported cases in Guangzhou City, China. *BioMed Res Int.* 2013;2013:283425.
63. Bicket MC, Long JJ, Pronovost PJ, et al. Prescription opioid analgesics commonly unused after surgery: a systematic review. *JAMA Surg.* 2017;152:1066-1071.

Figure 1. PRISMA flow chart of article selection.

Figure 2. Forest plot of proportion of patients taking prescription opioids after total hip arthroplasty. ES indicates effective size.

Figure 3. Forest plot of proportion of patients taking prescription opioids after total knee arthroplasty. ES indicates effective size.

**Key Points**

- A better understanding of the trajectory of opioid use following total hip or knee arthroplasty is needed to help guide clinicians and patients in care planning and harm prevention.
- Thirty studies were identified for full review and ultimate inclusion in this study, and the results showed that 1 in 5 patients may continue opioid use for longer than 3 months after total hip or knee arthroplasty.
- Clinicians should be aware of this trajectory of opioid consumption after surgery and focus on deprescribing.
| Study (Year Published) | Country | Procedure | Patient Age | Female, % | Funding Source(s) | Mental Disorder Comorbidity, % | Population | Preoperative | Postoperative |
|------------------------|---------|-----------|-------------|-----------|------------------|-------------------------------|------------|--------------|---------------|
| Bedard, Pugely, Dowdle, et al (2017) | US | THA | <50: 2.7% ≥50: 97.3% | 41 | NA | Anxiety or depression: 6.5 | Civilian | Monthly opioid prescription filling rate for the first 12 months postoperatively |
| Bedard, Pugely, Westermann, et al (2017) | US | TKA | <50: 1.4% ≥50: 98.6% | 63.8 | NA | Anxiety or depression: 37.5 | Civilian | Monthly opioid prescription filling rate for the first 12 months postoperatively |
| Bell et al (2020) | US | THA | Range: 20-85 <65: 19% 65-69: 25% 70-74: 28% | 67 | NA | Depression: 30 | Civilian | At least 1 opioid prescription filled 3-6 months postoperatively |
| Age Group | Burn et al. (2019) | Delay in US | Bolarinw a et al. (2019) | Delay in US THA |
|-----------|------------------|-------------|-----------------|-----------------|
| <40       | 0.6%             | 40.4%       | 0.6%            | 18%             |
| 40-49     | 2.8%             | 2.6%        | 0.8%            | 15.2%           |
| 50-59     | 10.9%            | 2.6%        | 10.9%           | 7.0%            |
| 60-69     | 31.2%            | 28.3%       | 15.2%           | 28.0%           |
| 70-79     | 39.3%            | 38.8%       | 31.2%           | 7.0%            |
| 80-84     | 14.1%            | 15.7%       | 21.9%           | 31.1%           |
| ≥85       | 0.8%             | 3.1%        | 0.8%            | 2.0%            |

**Depression:**
- Civilia (2019): NA
- At least 1 opioid prescription filled between 3 and 6 months after surgery

**EU/European Federation of Pharmaceutical Industries and Associations (EHDEN):**
- Depression: 5.2-7.1%
| Study                          | Country | Age Group | Proportion | Depression | Civilian | Chronic Opioid Use | Opioid Use Before Surgery |
|-------------------------------|---------|-----------|------------|------------|----------|-------------------|--------------------------|
| Cancienne et al (2018)<sup>27</sup> | US TKA  | 0.3% - 0.7% | 63.5% NA   | Depressed: 34.2% | Civilian: NA | At least 1 opioid prescription filled between 3 and 6 months after surgery |
| Cook et al (2019)<sup>28</sup>   | US TKA  | 0% - 2% | 61.8% NA   | Civilian: NA | Opioid users: Filled at least 2 opioid prescriptions within the 6 months before surgery Non-opioid users: Did not fill an opioid prescription within the 6 months before surgery At least 1 opioid or tramadol prescription filled within 3 months before surgery Monthly opioid or tramadol prescription filling rate for the first 12 months after surgery |
| DeMik et al (2020)<sup>29</sup> | US TKA  | NR NR NA NA NR Civilian | 52.5 | Anxiety or depression: 27.2 | Civilian | At least 1 opioid prescription filled |
| Dwyer et al (2018)<sup>30</sup>  | US TKA  | Mean (SD) age: 65.2 | Overall: 52.5 | Anxiety or depression: 27.2 | Civilian | At least 1 opioid prescription filled |

Note: THA: Total Hip Arthroplasty, TKA: Total Knee Arthroplasty, NR: Not reported, NA: Not applicable
| Study                        | Country | Procedure | Methodology | Mean Age | Age Range | Opioid Use Before Surgery | Opioid Use After Surgery |
|------------------------------|---------|-----------|-------------|----------|-----------|---------------------------|--------------------------|
| Franklin et al (2010)        | US      | TKA       | THA: 51.4 (10.7); TKA: 53.7 | 62.9 (11.5) TKA: 67.0 (9.3) | THA: 24.3 TKA: 30.2 | within 12 months before surgery, history of long-term opioid use, history of narcotic dependence |
| Goesling et al (2016)        | US      | THA, TKA  | Mean: 66.6 NA NR | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NR | At least 1 opioid prescription before surgery at 12 months after surgery, patient-reported opioid use on the day of surgery |
| Hadland smyth et al (2018)   | US      | TKA       | Median: 7 66% | NR | Veteran National Institute of Arthritis and Musculoskeletal and Skin Diseases | At least 90 days of continuous opioid use within 12 months before surgery |
| Hansen et al (2017)          | AU      | TKA       | Range: ≥18 | NA | NA | At least 90 days of continuous opioid use or at least 120 days of noncontinuous opioid use during days 91-365 after surgery |
| Study | Country | Procedure | Range: Median (IQR) | Australian Government National Health and Medical Research Council | Anxiety: 5th-95th percentile | Veteran: At least 90 days of continuous opioid use or 120 days of non-continuous opioid use within 275 days before surgery | Civilian: At least 1 opioid prescription filled during 1-4, 5-8, and 9-12 months after surgery |
|-------|---------|-----------|---------------------|--------------------------------------------------------------------------------|-----------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Inacio et al (2016) | AU | THA | ≥18 | 51.3 | 5th-95th percentile: 80 (76-84) | 12.3 | Bipolar: 0.3 | Anxiety: 17.8 | Depression: 2 | At least 90 days of continuous opioid use or 120 days of non-continuous opioid use within 275 days before surgery |
| Jorgensen et al (2018) | DK | THA, TKA | ≥18 | 57.9 | THA: 67.7 (11.0) | 54.1 TKA: 62.3 | 15 | 14.4 | 15.8 | At least 1 opioid prescription filled within 1 month before surgery |
| Kalbian et al (2019) | US | TKA | ≥18 | 57.7 | NA | NR | NA | NA | NA | Continued opioid use for beyond 6 months |
| Karhade et al (2019) | US | THA | ≥18 | 49.5 | NA | Depression: 9.3 | Psychosis: 0.5 | Depression: 15% | Veteran: 15% | NA | Continuous opioid prescriptions to at least 3 months after surgery |
| Kim et al (2018) | US | TKA | NR | NR | NA | NR | NA | Civilian: At least 30 days of continuous opioid use (minimum 20 mg/d in morphine equivalents) within 6 months after surgery | Civilian: At least 30 days of continuous opioid use (minimum 20 mg/d in morphine equivalents) within 6 months after surgery |
| Study                        | Country | Procedure | Mean or Range | Med (IQR) | VA Center | Depression | PTSD | Civilian | At least 30 days of continuous opioid use (minimum 20 mg/d in morphine equivalents) within 6 months after surgery |
|------------------------------|---------|------------|---------------|-----------|-----------|-------------|------|----------|----------------------------------------------------------------------------------------------------------|
| Kim et al (2020)³⁹          | US      | THA        | Mean: 63.1*   | 54.3*     | NA        | NR          |      | Civilian | At least 30 days of continuous opioid use (minimum 20 mg/d in morphine equivalents) within 3 months before surgery |
| Kuo et al (2019)³¹          | US      | TKA        | ≤50: 6%       | 6.5       | VA        | Depressions: 30.9 | PTSD: 18 | Veteran | At least 1 opioid prescription filled after postoperative month 12                                         |
| Namba et al (2016)³₂        | US      | THA        | Range: ≥18    | 58        | NA        | Anxiety: 9.9 | Bipolar: 0.8 | Depression: 8.7 | PTSD: 0.3                                                                                               |
| Namba, Inacio et al (2018)³³| US      | TKA        | Range: ≥18    | 62.7      | NA        | Anxiety: 10.6 | Bipolar: 0.8 | Depression: 9.4 | PTSD: 0.3                                                                                               |
| Namba, Singh et al (2018)³⁴ | US      | TKA        | Range: ≥18    | 62.9      | NA        | Anxiety: 10.9 | Bipolar: 0.9   | Depression: 9.6 | PTSD: 0.4                                                                                               |
| Study            | Country | Procedure | Age Groups | Pain Management Criteria | Days Before Surgery | Days After Surgery | Opioid Prescription Criteria |
|------------------|---------|------------|------------|--------------------------|---------------------|-------------------|-----------------------------|
| Politzer et al (2018) | US TKA | ≤44: 0.3% 45-59: 6.1% ≥60: 93.6% | 63.4 NA | NR Civilinan | At least 1 opioid prescription filled within 12 months before surgery |
| Prentice et al (2019) | US THA | ≥18: 58.5 NA | Anxiety: 9.9 Bipolar: 0.7 Depression: 8.8 PTSD: 0.4 Civilinan | NA | Opioid prescriptions for longer than 6 consecutive months after surgery |
| Ruddell et al (2020) | US THA TKA | ≥18: 63.1 NA | THA: 58.6 TKA: 66 | Anxiety: 9.9 Bipolar: 0.7 Depression: 8.8 PTSD: 0.4 Civilinan | Any opioid prescription filled within 30 days before surgery |
| Schwartz et al (2020) | US THA | ≥18: 47.7 NA | Depression: 7.54 Civilinan | NA | At least 1 opioid prescription between 6 and 12 months after surgery |
| Soffin et al (2021) | US THA TKA | ≥18: 47.84 NA | Discharge antidepressant: 0.84 Discharge anxiolytic: 2.64 | Civilinan | Opioid prescription in the year before surgery |
|                   |         | female: 57 (52-61); males: | Discharge antidepres | Opioid prescriptions or prescriptions for at least 120 pills between 90 days to 1 year | At least 10 opioid prescriptions |
|                   |         |               | s: 57 (52-61); males, | s: 57 (52-61); males, |
|                | US | THA | NR | NR | NA | NR | Civilian | Opioid prescription during 6 months before surgery | Continued opioid use past 6 months after surgery |
|----------------|----|-----|----|----|----|----|---------|---------------------------------------------------|--------------------------------------------------|
| *Tan et al (2020)* |    |     |    |    |    |    |         | Continued opioid use                                 | At least 1 opioid prescription filled within the 6 months before surgery |
| *Wilt et al (2020)* |    |     |    |    |    |    |         | At least 1 opioid prescription filled after surgery |                                                                   |

Abbreviations: AU, Australia; DK, Denmark; IQR, interquartile range; NA, not applicable; NR, not reported; PTSD, posttraumatic stress disorder; SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty; UK, United Kingdom; US, United States.

*a* Age reported differently across studies.

*b* Non-opioid users were participants who did not meet the definitions of opioid user unless otherwise specified. Definitions of preoperative opioid use were not recorded in this table for studies that did not report percentage of postoperative opioid user stratified by preoperative opioid use.

*c* Burn et al (2020) reported patient characteristics separately for each of the 5 databases; therefore, the range of the reported data is shown in this table.

*d* Value calculated from data reported in the studies.
| Study (Year Published) | Sample Size | Total Population | Preoperative Use | Use |
|------------------------|-------------|------------------|------------------|-----|
| **Total Hip Arthroplasty** |             |                  |                  |     |
| Bedard, Pugely, Dowdle et al (2017) | 37,393 | 3 mo: 6,979 (18.7) | 3 mo: 5,516 (38.5) | 3 mo: 730 (4.8) |
| | 5,643 | 6 mo: 4,619 (32.3) | 6 mo: 460 (3.0) |     |
| | 5,256 | 9 mo: 4,326 (30.2) | 9 mo: 430 (2.8) |     |
| | (2017) | 5,139 (13.7) | 12 mo: 4,012 | 12 mo: 440 (2.9) |
| Bell et al (2020) | 5,304 | 3 mo: 2,595 (48.9) | 3 mo: 2,056 (58.1) | 3 mo: 539 (30) |
| Bolarinwa et al (2019) | 55,354 | 3 mo: 14,996 (27) |                  |     |
| Cook et al (2019) | 22,701 | 12 mo: (20.7) | 12 mo: (47.0) | 12 mo: (10.0) |
| Dwyer et al (2018) | 197 | 3 mo: 0 (0.0) |                  | 3 mo: 0 (0.0) |
| Goesling et al (2016) | 331 | 3 mo: 43 (14.5) | 3 mo: 34 (37.8) | 3 mo: 9 (4.3) |
| | 34 (12.9) | 6 mo: 26 (34.7) | 6 mo: 8 (4.2) |     |
| Inacio et al (2016) | 9,525 | 3 mo: 492 (5.2) | 3 mo: 302 (50.9) | 3 mo: 190 (2.1) |
| Jorgensen et al (2016) | 4,849 | 9 mo: 662 (13.7) | 9 mo: 436 (33.8) | 9 mo: 226 (6.3) |
| Study                          | Total n | 3 mo | 6 mo | 9 mo |
|-------------------------------|---------|------|------|------|
| al (2018)                     | 5,507   |      |      |      |
| Karhade et al (2019)          | 256     | 15 (5.9) | 13 (24.1) | 2 (1.0) |
| Namba et al (2016)            | 12,859  | 3,461 (27) |      |      |
| Prentice et al (2019)         | 12,560  | 3,506 (27.9) |      |      |
| Ruddell (2020)                | 198     | 24 (12.1) |      |      |
| Schwartz et al (2020)         | 171,258 |      | 33,504 (26.3) |      | (patients with 1 year of postoperative data: 127,510) |
| Soffin et al (2021)           | 29,038  | 2,333 (8.0) |      |      |
| Tan et al (2020)              | 619     | 65 (10.5) | 54 (25.0) | 11 (2.7) |
| Wilt et al (2020)             | 676     | 80 (11.8) | 58 (28.3) | 22 (4.7) |
| Study                  | N     | 3 mo | 6 mo | 9 mo | 12 mo |
|------------------------|-------|------|------|------|-------|
| Bedard et al (2017)    | 73,959| 18,451 (24.9) | 11,850 | 3,046 (10.2) |
| Pugely et al (2017)    | 73,959| 12,070 (16.3) | (50.4) | 1,191 (4.0) |
| Westermann et al (2017) | 73,959| 10,995 (14.9) | 9,024 (38.3) | 951 (3.2) |
| Burn et al (2019)      | 250,377| 87,460 (34.9) |       |       |
| Cancienne et al (2018) | 113,337| 35,770 (31.6) |       |       |
| Cook et al (2019)      | 46,667| 22,625 (21.0) | (50.1) |       |
| DeMik et al (2020)     | 107,973| 32,638 (30.2) | 22,260 | 10,378 |
| Dwyer et al (2018)     | 186   | 0 (0.0) |       |       |
| Franklin et al (2010)  | 6,346 | 351 (6.1) | 221 (16.3) | 130 (3.0) |
| Study                        | n    | 3 mo: | 6 mo: | 12 mo: |
|-----------------------------|------|-------|-------|--------|
| Goesling et al (2016)       | 243  | 54 (24.2) | 26 (48.1) | 28 (16.6) |
| Hadlandsmyth et al (2018)   | 6,653| 26 (26) | 82 (0)  | 12 (0)  |
| Hansen et al (2017)         | 15,020| 787 (5.2) | 479 (66.5) | 308 (21.2) |
| Jorgensen et al (2018)      | 4,126| 765 (18.5) | 440 (51.9) | 325 (9.9) |
| Kalbian et al (2019)        | 676  | 80 (11.8) |       |        |
| Kim et al (2018)            | 338  | 37 (10.9) | 23 (42.6) | 14 (4.9) |
| Kuo et al (2019)            | 33,927|       | 46 (0)  |        |
| Namba, Inacio et al (2018)  | 24,105| 9,914 (41.5) | 7,431 (31.4) | 6,946 (29.6) |
| Namba, Singh et al (2018)   | 23,726| 9,993 (42.1) | 7,638 (32.2) | 7,218 (30.4) |
| Politzer et al (2018)       | 66,950| 14,286 (21.3) | 12,762 (5.0) | (34.8)* |
| Ruddell (2020)              | 309  | 49 (15.9) |       |        |
Soffin et al (2021)\textsuperscript{50}

\textsuperscript{a}Number (percentage) of postoperative opioid users at various postoperative time points.

\textsuperscript{b}Value calculated from data reported in the studies.
Table 3. Sensitivity Meta-analysis Results: Total Hip Arthroplasty

| Time  | Proportion | 95% Confidence Interval | Proportion | 95% Confidence Interval | Proportion | 95% Confidence Interval |
|-------|------------|--------------------------|------------|--------------------------|------------|--------------------------|
| 3 months | 10%       | 6%-15%                   | 47%        | 34%-60%                  | 20%        | 13% –26%                  |
|        | 13%       | –3% to 30%               | 45%        | 29%-61%                  | 21%        | 14%-28%                  |
| 6 months | 3%        | 2%-4%                    | 29%        | 25%-33%                  | 17%        | 12%-21%                  |
| 9 months | 3%        | 3%-3%                    | 31%        | 30%-31%                  | 19%        | 13%-24%                  |
| 12 months | 4%       | 4%-5%                    | 33%        | 32%-33%                  | 16%        | 15%-16%                  |

*Subset excluding studies that involved military population.
Table 4. Sensitivity Meta-analysis Results: Total Knee Arthroplasty

| Time Point | Opioid-Naïve Patients | Opioid-Tolerant Patients | Total Sample |
|------------|------------------------|--------------------------|--------------|
|            | Proportion | 95% Confidence | Proportion | 95% Confidence | Proportion | 95% Confidence |
| 3 months   | 11%        | 5%-18%          | 60%        | 53%-68%          | 26%        | 19%-33%          |
|            | 14%        | 9%-19%          | 50%        | 50%-51%          | 29%        | 22%-36%          |
| 6 months   | 6%         | 4%-8%           | 45%        | 41%-50%          | 20%        | 17%-24%          |
|            | 38%        | 35%-41%         | 21%        | 17%-25%          |            |                |
| 9 months   | 7%         | 3%-10%          | 40%        | 37%-43%          | 23%        | 17%-28%          |
| 12 months  | 6%         | 2%-9%           | 41%        | 30%-52%          | 21%        | 12%-29%          |
|            | 37%        | 25%-49%         | 16%        | 11%-21%          |            |                |

*Subset excluding studies that involved military population.*
Records identified \((n = 1,363)\)

Records removed before screening: Duplicate records removed \((n = 381)\)

Records screened \((n = 982)\)

Records excluded \((n = 900)\)

Reports sought for retrieval \((n = 82)\)

Reports not retrieved \((n = 0)\)

Reports assessed for eligibility \((n = 82)\)

Full-text articles excluded \((n = 52)\):
- No outcome of interest \((n = 19)\)
- Hip and knee surgery data combined \((n = 13)\)
- Data combined with other surgeries \((n = 13)\)
- Cancer patients \((n = 2)\)
- Duplicated data \((n = 1)\)
- Follow-up <3 months \((n = 3)\)
- Follow-up time not stated \((n = 1)\)

Studies included in review \((n = 30)\)
### Figure 2

**Total Hip Replacement (Total)**

| Study                  | ES (95% CI)   | % Weight |
|------------------------|--------------|----------|
| **3 Months**           |              |          |
| Bedard, Pugely, Dowdle et al. (2017) | 0.19 (0.18, 0.19) | 10.08   |
| Bell et al. (2020)     | 0.49 (0.48, 0.50) | 10.05   |
| Bolariwma et al. (2019) | 0.27 (0.27, 0.27) | 10.08   |
| Goesling et al. (2016) | 0.14 (0.11, 0.19) | 9.75    |
| Inacio et al. (2019)   | 0.05 (0.06, 0.06) | 10.08   |
| Kerhate et al. (2019)  | 0.06 (0.06, 0.07) | 10.08   |
| Namba et al. (2016)    | 0.27 (0.27, 0.28) | 10.07   |
| Prontice et al. (2019) | 0.28 (0.27, 0.29) | 10.07   |
| Ruddell et al. (2020)  | 0.12 (0.06, 0.17) | 9.65    |
| Stoffin et al. (2021)  | 0.08 (0.08, 0.08) | 10.08   |
| **Subtotal (I² = 99.93%, p = 0.00)** | 0.20 (0.13, 0.26) | 100.00 |
| **6 Months**           |              |          |
| Bedard, Pugely, Dowdle et al. (2017) | 0.15 (0.15, 0.15) | 12.81   |
| Goesling et al. (2016) | 0.13 (0.08, 0.18) | 11.74   |
| Kim et al. (2019)      | 0.06 (0.03, 0.09) | 12.25   |
| Namba et al. (2016)    | 0.24 (0.23, 0.25) | 12.76   |
| Prontice et al. (2019) | 0.25 (0.24, 0.25) | 12.76   |
| Schwartz et al. (2020) | 0.26 (0.26, 0.27) | 12.82   |
| Tan et al. (2020)      | 0.11 (0.06, 0.13) | 12.41   |
| Will et al. (2020)     | 0.12 (0.08, 0.15) | 12.41   |
| **Subtotal (I² = 99.76%, p = 0.00)** | 0.17 (0.12, 0.21) | 100.00 |
| **9 Months**           |              |          |
| Bedard, Pugely, Dowdle et al. (2017) | 0.14 (0.14, 0.14) | 25.08   |
| Jorgensen et al. (2018) | 0.14 (0.13, 0.15) | 24.92   |
| Namba et al. (2016)    | 0.23 (0.23, 0.24) | 25.00   |
| Prentice et al. (2019) | 0.24 (0.23, 0.25) | 23.00   |
| **Subtotal (I² = 99.67%, p = 0.00)** | 0.19 (0.13, 0.24) | 100.00 |
| **12 Months**          |              |          |
| Bedard, Pugely, Dowdle et al. (2017) | 0.14 (0.13, 0.14) | 72.81   |
| Cook et al. (2019)     | 0.21 (0.20, 0.21) | 27.19   |
| **Subtotal (I² = %, p = .)** | 0.16 (0.15, 0.16) | 100.00 |

**Proportion With Opioid Use**
### Figure 3

#### Total Knee Replacement (Total)

| Study                                      | ES (95% CI) | Weight |
|--------------------------------------------|-------------|--------|
| **3 Months**                               |             |        |
| Bedard, Puget, Westermann et al. (2017)    | 0.25 (0.23, 0.26) | 9.17   |
| Burns et al. (2015)                        | 0.38 (0.35, 0.35) | 9.17   |
| Caronni et al. (2018)                      | 0.32 (0.31, 0.32) | 9.17   |
| DeMik et al. (2020)                        | 0.30 (0.29, 0.31) | 9.17   |
| Goossens et al. (2016)                     | 0.24 (0.19, 0.30) | 8.85   |
| Hadland et al. (2018)                      | 0.26 (0.25, 0.27) | 9.15   |
| Hanssen et al. (2017)                      | 0.05 (0.02, 0.06) | 9.17   |
| Nambo, Inacio et al. (2018)                | 0.41 (0.41, 0.42) | 9.16   |
| Nambo, Singh et al. (2018)                 | 0.43 (0.43, 0.43) | 9.16   |
| Ruideli et al. (2020)                      | 0.10 (0.09, 0.12) | 8.99   |
| Sohn et al. (2021)                         | 0.11 (0.11, 0.11) | 9.17   |
| **Sum total (I^2 = 89.97%, p = 0.00)**     | 0.06 (0.05, 0.07) | 9.17   |
| **6 Months**                               |             |        |
| Bedard, Puget, Westermann et al. (2017)    | 0.16 (0.16, 0.17) | 11.90  |
| DeMik et al. (2020)                        | 0.01 (0.01, 0.02) | 11.59  |
| Goossens et al. (2016)                     | 0.09 (0.08, 0.09) | 9.04   |
| Hadland et al. (2018)                      | 0.15 (0.15, 0.15) | 11.59  |
| Klisian et al. (2019)                      | 0.11 (0.10, 0.11) | 11.59  |
| Kim et al. (2019)                          | 0.11 (0.10, 0.11) | 11.59  |
| Nambo, Inacio et al. (2018)                | 0.31 (0.30, 0.32) | 11.57  |
| Nambo, Singh et al. (2018)                 | 0.32 (0.32, 0.33) | 11.57  |
| Polkner et al. (2018)                      | 0.21 (0.21, 0.22) | 11.57  |
| **Sum total (I^2 = 99.79%, p = 0.00)**     | 0.09 (0.17, 0.24) | 10.00  |
| **9 Months**                               |             |        |
| Bedard, Puget, Westermann et al. (2017)    | 0.18 (0.15, 0.19) | 20.05  |
| DeMik et al. (2020)                        | 0.18 (0.18, 0.19) | 20.05  |
| Jorgensen et al. (2019)                    | 0.18 (0.17, 0.18) | 19.57  |
| Nambo, Inacio et al. (2018)                | 0.28 (0.27, 0.29) | 20.01  |
| Nambo, Singh et al. (2018)                 | 0.30 (0.30, 0.31) | 20.01  |
| **Sum total (I^2 = 99.69%, p = 0.00)**     | 0.23 (0.17, 0.29) | 10.00  |
| **12 Months**                              |             |        |
| Bedard, Puget, Westermann et al. (2017)    | 0.15 (0.14, 0.15) | 16.68  |
| Coker et al. (2019)                        | 0.23 (0.23, 0.24) | 16.67  |
| DeMik et al. (2020)                        | 0.19 (0.19, 0.19) | 16.68  |
| Franklin et al. (2019)                     | 0.06 (0.06, 0.07) | 16.66  |
| Hadland et al. (2018)                      | 0.13 (0.12, 0.14) | 16.66  |
| Kuo et al. (2018)                          | 0.46 (0.45, 0.47) | 16.67  |
| **Sum total (I^2 = 99.96%, p = 0.00)**     | 0.02 (0.02, 0.02) | 100.00 |

**Proportion With Opioid Use**